Skip to content
Evigrade
MajorTriptan, selective 5HT1B/1D receptor agonist×Macrolide antibiotic

Updated · Methodology

Mechanism

CYP3A4 is the main liver enzyme that metabolises eletriptan (eletriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In clinical studies, erythromycin 1000 mg increased the peak concentration of eletriptan 2-fold and the area under the concentration curve (AUC) 3.6-fold (AEMPS). The eletriptan half-life rose from 4.6 to 7.1 hours (AEMPS). The Spanish eletriptan SmPC calls erythromycin a specific and strong CYP3A4 inhibitor, while the Spanish erythromycin SmPC classes it as a moderate inhibitor of CYP3A4 and of the transporter P-glycoprotein (eletriptan and erythromycin SmPCs, AEMPS). The US eletriptan label gives the same data rounded: about a 2-fold increase in peak concentration and about a 4-fold increase in AUC (eletriptan label, US Food and Drug Administration, FDA).

Symptoms

The documents do not describe what effects the higher eletriptan exposure had in the erythromycin study. Adverse events of eletriptan become more frequent as the dose rises, and the most common are weakness, drowsiness, nausea and dizziness. Doses of 60 mg or more caused small, transient rises in blood pressure, more marked in older people and in kidney impairment (eletriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). An overdose may cause hypertension or more serious cardiovascular symptoms (AEMPS). Eletriptan can cause chest pain and tightness, which may be intense and spread to the throat. Coronary vasospasm and life-threatening arrhythmias have been reported with 5-HT1 agonists, and in rare cases myocardial ischaemia or infarction and severe rises in blood pressure (eletriptan SmPC, AEMPS, and eletriptan label, US Food and Drug Administration, FDA).

Management

Do not use eletriptan with strong inhibitors of the enzyme CYP3A4. The eletriptan summary of product characteristics (SmPC) names erythromycin among them (eletriptan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish SmPC does not list the combination as a contraindication (AEMPS). The US eletriptan label does not include erythromycin in its list of contraindicated strong CYP3A4 inhibitors either (eletriptan label, US Food and Drug Administration, FDA). The US label says not to use eletriptan for at least 72 hours after treatment with strong CYP3A4 inhibitors (FDA). The Spanish documents give no interval, and the half-life of erythromycin is about 2 hours (erythromycin SmPC, AEMPS). The Spanish erythromycin SmPC says to closely monitor the levels of drugs metabolised by cytochrome P450 enzymes during erythromycin treatment and to adjust their dose if needed (erythromycin SmPC, AEMPS). If eletriptan has nevertheless been taken during an erythromycin course and chest pain or tightness suggestive of cardiac ischaemia appears, withhold further doses and arrange a cardiac assessment (eletriptan SmPC, AEMPS). Stop eletriptan if arrhythmias occur, and monitor blood pressure during treatment (eletriptan FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Eletriptan

Other interactions with Erythromycin